


Claims

Claims 1-14. (canceled)

15. (currently amended) A polypharmacophore represented by formula (II):



(II)

wherein:

R₁ is -CO₂R₄ or [[-CO₂N(R₄)₂]] -CON(R₄)₂;

R₂ represents independently for each occurrence H, F, Cl, Br, or I;

R₃ represents independently for each occurrence H, F, Cl, Br, or I;

R₄ represents independently for each occurrence H or alkyl; and

the stereochemical configuration of the carbon-carbon double bond is *Z*, *E*, or a mixture of *Z* and *E*.

Claims 16-54. (canceled)


55. (previously presented) The polypharmacophore of claim 15, wherein R₂ is F.

56. (previously presented) The polypharmacophore of claim 15, wherein R₂ is F and R₃ is H.

57. (previously presented) The polypharmacophore of claim 15, wherein R₁ is CO₂R₄.

58. (previously presented) The polypharmacophore of claim 15, wherein R₁ is CO₂R₄ and R₄ is H.

59. **(previously presented)** The polypharmacophore of claim 15, wherein said compound is selected from group consisting of:



60. **(previously presented)** A pharmaceutical composition, comprising:

a polypharmacophore of claim 15, 55, 56, 57, 58 or 59, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.